Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, raises $600 million.
Investors announced one of the biggest private financing rounds of the year for a biotech company, pouring $600 million into startup Kailera Therapeutics.
The financing was led by Bain Capital’s private equity group and included Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada’s national pension plan.
Author's summary: Kailera Therapeutics raises $600 million in funding.
- The deal underlines the persistent heightened attention being paid to weight loss drugs.
- Kailera’s Series B round was announced almost exactly one year after the startup launched with $400 million.
- The investment comes shortly after Pfizer announced plans to buy another privately held obesity drug developer, Metsera, for $4.9 billion.